Oncolytics Biotech, Inc. (ONCY)
0.631
-0.01
(-1.59%)
USD |
NASDAQ |
Oct 02, 16:00
0.6246
-0.01
(-1.01%)
After-Hours: 20:00
Oncolytics Biotech Enterprise Value : 74.98M for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 74.98M |
| October 01, 2026 | 76.25M |
| September 30, 2026 | 79.62M |
| September 29, 2026 | 80.40M |
| September 28, 2026 | 78.97M |
| September 25, 2026 | 81.50M |
| September 24, 2026 | 80.99M |
| September 23, 2026 | 80.65M |
| September 22, 2026 | 85.24M |
| September 21, 2026 | 91.84M |
| September 18, 2026 | 92.30M |
| September 17, 2026 | 92.30M |
| September 16, 2026 | 92.15M |
| September 15, 2026 | 93.55M |
| September 14, 2026 | 97.63M |
| September 11, 2026 | 89.25M |
| September 10, 2026 | 92.55M |
| September 09, 2026 | 95.42M |
| September 08, 2026 | 96.67M |
| September 04, 2026 | 101.43M |
| September 03, 2026 | 103.08M |
| September 02, 2026 | 106.01M |
| September 01, 2026 | 101.03M |
| August 31, 2026 | 100.80M |
| August 28, 2026 | 103.10M |
| Date | Value |
|---|---|
| August 27, 2026 | 102.27M |
| August 26, 2026 | 102.97M |
| August 25, 2026 | 103.70M |
| August 24, 2026 | 101.54M |
| August 21, 2026 | 101.41M |
| August 20, 2026 | 96.25M |
| August 19, 2026 | 99.91M |
| August 18, 2026 | 101.63M |
| August 17, 2026 | 98.87M |
| August 14, 2026 | 100.28M |
| August 13, 2026 | 96.04M |
| August 12, 2026 | 99.00M |
| August 11, 2026 | 98.54M |
| August 10, 2026 | 96.39M |
| August 07, 2026 | 96.35M |
| August 06, 2026 | 96.12M |
| August 05, 2026 | 95.69M |
| August 04, 2026 | 97.35M |
| August 03, 2026 | 92.93M |
| July 31, 2026 | 90.22M |
| July 30, 2026 | 90.18M |
| July 29, 2026 | 90.01M |
| July 28, 2026 | 95.06M |
| July 27, 2026 | 96.06M |
| July 24, 2026 | 97.56M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 8.834B |
| Sangamo Therapeutics, Inc. | 52.85M |
| Sarepta Therapeutics, Inc. | 2.106B |
| Anixa Biosciences, Inc. | 87.06M |
| Vicapsys Life Sciences, Inc. | 21.53M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -9.442M |
| Total Expenses (Quarterly) | 9.442M |
| EPS Diluted (Quarterly) | -0.0788 |
| Earnings Yield | -43.19% |
| Normalized Earnings Yield | -43.25 |